Trevi Therapeutics, Inc. (TRVI): Total Assets
$193.44M
As of 2025-12-31
$330.52M
As of 2026-06-30
+16.3%
3-year compound annual growth
+32.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $193.44M | +74.4% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $110.90M | +24.0% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $89.40M | -27.3% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $123.02M | +219.7% | 2024-03-20, Balance as of period end |
| 2021-12-31 | $38.48M | -18.4% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $47.13M | -21.4% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $60.00M | +470.0% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $10.53M | n/a | 2020-03-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $193.44M | +74.4% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $192.35M | -12.7% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $198.10M | -30.2% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $200.46M | -29.8% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $185.55M | +28.7% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $184.99M | -38.0% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $184.69M | +4.0% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $182.62M | +83.4% |
| COMPASS Pathways plc (CMPS) | 2025-12-31 | $210.35M | -1.6% |
Compare TRVI, ACET, FHTX, URGN side by side · Screen every company in Pharmaceutical Preparations ↗